PPCB earnings analysis
What we found in PPCB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
For the three months ended March 31, 2026, Propanc Biopharma reported no revenue, maintaining its position from the preceding year. The company reduced its net loss significantly to $6.36 million from $54.07 million year-over-year, mainly due to decreased administrative expenses. There continues to be substantial concern regarding liquidity, with cash decreasing to $443,702 as of March 31, 2026, from $12.09 million as of June 30, 2025, raising questions regarding the company's ability to continue operations without additional financing.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Reduction in Net Loss
- Net loss decreased to $6,360,336 for Q3 2026, from $54,067,346 in Q3 2025, marking a substantial improvement.
- Decrease in Administrative Expenses
- Administrative expenses dropped sharply to $6,219,644 for Q3 2026, down by approximately $46.8 million from $53,068,147 in Q3 2025.
- No Revenue Generated Again
- For the three months ended March 31, 2026, the company reported no revenue, consistent with the prior year.
- Decrease in Interest Expense
- Interest expense declined to $38,270 for Q3 2026 compared to $104,042 for Q3 2025, showing better management of financing costs.
- Positive Development in Clinical Programs
- Initiation of a Phase 1b clinical study for the lead asset PRP indicates ongoing progression in research and development.
- Cash Position Still Relatively Large
- Despite a reduction in cash to $443,702, the company had previously held $12,088,000, indicating a significant depletion.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Financial Losses
- The company has incurred net losses totaling $14,289,468 for the nine months ended March 31, 2026.
- Limited Cash Reserves
- Cash reserves fell to $443,702 as of March 31, 2026, down from $12,088,000 at the end of the prior fiscal year.
- Dependence on External Financing
- Management indicated it does not have enough cash to meet obligations over the next 12 months without securing additional financing.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.39
What they said about what is next.
Future outlook deferred to earnings press release / call for further quantitative insights.
The filing reads better than the one before it.
What came before.
- 10-Q · February 17, 2026
- Propanc reported zero revenue for the three months ended December 31, 2025 and a net loss of $3,091,394 (EPS $(0.30)). The company raised cash during the period (proceeds from sale of common stock $3,314,458 and…
- 10-Q · November 14, 2025
- Propanc reported zero revenue and a quarterly net loss of $4,837,738 (EPS $(0.39)) for the three months ended September 30, 2025, vs. a net loss of $354,310 in the prior-year quarter. Operating expenses surged to…
- 10-Q · February 14, 2025
- Propanc reported no revenue for the quarter or six months ended December 31, 2024. Operating expenses declined materially (three months $213,382 vs $438,064 prior year), producing smaller losses (quarter net loss…
- 10-Q · February 20, 2024
- Propanc Biopharma remains a pre-revenue, development-stage company (Revenue $0) that reported a quarterly net loss of $(584,384) and diluted loss per share of $(0.03) for the quarter ended December 31, 2023. Cash rose…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PPCB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever